<DOC>
	<DOC>NCT03051607</DOC>
	<brief_summary>Phase 3, international, multicenter, open-label 12 month safety study.</brief_summary>
	<brief_title>A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease Experiencing End of Dose "Wearing-Off"</brief_title>
	<detailed_description>Each patient will participate for up to 62 weeks, which includes a Screening Period, followed by a Baseline Visit and open-label treatment for 1 year with a safety Follow-up 4 weeks after the last treatment. - Screening Period: up to 6 weeks. - Open-Label Treatment Period: 52 weeks (1 year) - Post-Treatment Safety Follow Up: 4 weeks.</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Patient understands study requirements and has given his/her written informed consent on an Institutional Review Board (IRB) or Independent Ethics Committee (IEC) approved consent form. Parkinson's disease diagnosis consistent with UK Parkinson's Disease Society Brain Bank Diagnostic criteria Minimum of 3 years since diagnosis. Meet Hoehn and Yahr PD stage Good response to levodopa Stable regimen of antiPD medications Patients must have been taking a levodopacontaining antiPD medication continuously for at least the previous 12 months Patient has documented a minimum amount of Off time. If of childbearing potential (male and female) must use an acceptable method of contraception Previous tozadenant study participation Current or recent participation in another study. Secondary or atypical parkinsonism Neurosurgical intervention for PD (except DBS if electrode placement has been performed over 12 months prior to screening) Patient is taking apomorphine, budipine, istradefylline, tolcapone, or DUOPA™/Duodopa® Treatment with excluded medications Untreated or uncontrolled hyperthyroidism or hypothyroidism Clinically significant outofrange laboratory MMSE out of range Current episode of major depression (stable treatment for depression is permitted). Recent suicide attempt or suicidal ideation type 4 or type 5 of the ColumbiaSuicide Severity Rating Scale (CSSRS) Women lactating or pregnant Hypersensitivity to any components of tozadenant or excipients Abnormal findings on the physical or neurological examination, or medical history that would make the patient unsuitable for the study History of hepatitis or cholangitis</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Motor Fluctuations</keyword>
	<keyword>Off time</keyword>
	<keyword>On time</keyword>
	<keyword>Dyskinesia</keyword>
</DOC>